International Journal of Medical and Health Research
www.medicalsciencejournal.com
ISSN: 2454-9142
Received: 17-03-2025, Accepted: 16-04-2025, Published: 02-05-2025
Volume 11, Issue 3, 2025, Page No. 1-8

Role of immunotherapy in treating oral squamous cell carcinoma: A comprehensive review

Vijay Kumar[1], Mohammad Saleem[1], Amandeep Kumar[1], Bhawna Suryawanshi[2]
[1] Department of Paramedical Sciences, Swami Vivekanand Group of Institutes, Banur, Punjab, India
[2] Assistant Professor, Department of Paramedical Sciences Swami Vivekanand Group of Institutes, Banur, Punjab, India

Abstract
Oral squamous cell carcinoma (OSCC) remains a significant global health challenge with high mortality rates, particularly in advanced stages, despite advancements in traditional treatment modalities such as surgery, radiation, and chemotherapy. In recent years, immunotherapy has emerged as a promising strategy by harnessing the body's immune system to combat OSCC. However, the highly immunosuppressive tumor microenvironment (TME), composed of regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and immunosuppressive cytokines, promotes immune evasion and tumor progression, limiting the effectiveness of immunotherapeutic interventions.
Immune checkpoint inhibitors (ICIs), targeting molecules such as PD-1/PD-L1 and CTLA-4, have shown potential in restoring T cell activity and improving survival outcomes, with pembrolizumab and nivolumab demonstrating efficacy in recurrent or metastatic OSCC. Nevertheless, variable response rates highlight the need for predictive biomarkers, including PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI), to enhance patient selection for ICI therapy. Additionally, monoclonal antibodies targeting epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) offer therapeutic benefits when combined with conventional treatments.
Emerging immunotherapeutic strategies, such as cancer vaccines (peptide-based and dendritic cell vaccines) and adoptive cell therapies, including chimeric antigen receptor (CAR)-T cell therapy, show potential in overcoming immune resistance. However, challenges such as immune-related adverse events (irAEs), tumor heterogeneity, and immune escape mechanisms hinder the widespread success of immunotherapy.
Future research must focus on optimizing combination therapies, exploring resistance pathways, and identifying novel immunotherapeutic targets to enhance treatment efficacy and improve patient outcomes. This review underscores the evolving landscape of OSCC immunotherapy, highlighting both current advancements and future directions in the pursuit of more effective and durable treatment strategies.

Keywords: Modalities, evasion, monoclonal, efficacy, therapeutic

Introduction

Oral squamous cell carcinoma (OSCC) is the most prevalent malignancy of the oral cavity, accounting for over 90% of oral cancers globally. Despite advances in surgical techniques, radiation therapy, and chemotherapy, OSCC remains associated with high morbidity, frequent recurrence, and a dismal five-year survival rate of approximately 50%. This poor prognosis underscores the pressing need for novel and more effective therapeutic strategies. Major risk factors contributing to OSCC include tobacco use, excessive alcohol consumption, human papillomavirus (HPV) infection, and genetic predisposition, making it a multifactorial disease with complex pathophysiology.

The immune system plays a pivotal role in controlling tumor development through a process known as cancer immunoediting, which consists of three phases: elimination, equilibrium, and escape. However, OSCC tumors often develop sophisticated mechanisms to evade immune surveillance. These include the upregulation of immune checkpoint molecules such as programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), recruitment of immunosuppressive cells such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and secretion of inhibitory cytokines like transforming growth factor-beta (TGF-β) and interleukin-10 (IL-10). These mechanisms collectively create an immunosuppressive tumor microenvironment (TME), facilitating tumor progression and reducing the efficacy of conventional treatments.

In recent years, immunotherapy has emerged as a revolutionary approach in cancer treatment, harnessing the body's immune system to recognize and eliminate malignant cells. Immune checkpoint inhibitors (ICIs), including anti-PD-1/PD-L1 (e.g., pembrolizumab, nivolumab) and anti-CTLA-4 antibodies, have demonstrated significant clinical efficacy in head and neck squamous cell carcinoma (HNSCC), including OSCC. Clinical trials have shown that these agents improve overall survival in patients with recurrent or metastatic OSCC, leading to their approval by the U.S. Food and Drug Administration (FDA). However, not all patients respond to ICIs, highlighting the need for predictive biomarkers and combination strategies to enhance therapeutic efficacy.

Beyond ICIs, other immunotherapeutic approaches are being actively investigated for OSCC treatment. These include monoclonal antibodies targeting epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), which have shown promise when combined with chemotherapy and radiation therapy. Additionally, cancer vaccines, such as peptide-based and dendritic cell vaccines, aim to activate the immune system against OSCC-specific antigens. Emerging strategies like chimeric antigen receptor (CAR)-T cell therapy and tumor-infiltrating lymphocyte (TIL) therapy offer further potential for boosting anti-tumor immunity.

Despite these promising advances, several challenges remain. The heterogeneity of OSCC, coupled with the dynamic nature of the TME, complicates the development of universally effective immunotherapies. Furthermore, immune-related adverse events (irAEs) caused by excessive immune activation can significantly impact patient safety and treatment outcomes. Thus, a deeper understanding of OSCC's immune landscape and the mechanisms of immune evasion is essential for developing more effective, personalized immunotherapeutic strategies.

This research paper aims to explore the evolving landscape of immunotherapy in OSCC, examining current treatment modalities, challenges, and future directions. By elucidating the interplay between the immune system and OSCC, this study seeks to contribute to the development of more effective and targeted immunotherapeutic approaches, ultimately improving patient outcomes.

Material and Methods

1. Study Design and Protocol

A systematic review of published literature was conducted to evaluate the role of immunotherapy in oral squamous cell carcinoma (OSCC). The study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to ensure methodological rigor and transparency. The review protocol was designed to systematically identify, evaluate, and synthesize relevant evidence on immunotherapy approaches in OSCC.

2. Data Sources and Search Strategy

Relevant articles were retrieved from the following electronic databases:

- **PubMed**
- **Scopus**
- **Web of Science**
- **Google Scholar**

The search was conducted using a combination of Medical Subject Headings (MeSH) terms and keywords related to OSCC and immunotherapy. The search terms included:

- "oral squamous cell carcinoma"
- "immunotherapy"
- "immune checkpoint inhibitors"
- "tumor microenvironment"
- "monoclonal antibodies"

Boolean operators (**AND**, **OR**) were applied to refine the search results. For instance:

- ("oral squamous cell carcinoma" OR "OSCC") AND ("immunotherapy" OR "immune checkpoint inhibitors") AND ("tumor microenvironment" OR "monoclonal antibodies").

To ensure a comprehensive review, reference lists of included articles were manually screened to identify additional relevant studies.

3. Inclusion and Exclusion Criteria

The selection process was based on pre-defined inclusion and exclusion criteria:

Inclusion Criteria

- Articles published between 2000 and 2024.
- Peer-reviewed studies, including clinical trials, preclinical studies, and systematic reviews focused on immunotherapy in OSCC.
- Studies reporting on treatment outcomes, mechanisms, or efficacy of immunotherapy.
- Articles published in English.

Exclusion Criteria

- Case reports, editorials, letters, and conference abstracts.
- Articles not available in English.
- Studies lacking sufficient data on immunotherapy outcomes or methodology.
- Studies with a high risk of bias based on quality assessment tools.

4. Data Extraction and Synthesis

Two independent reviewers systematically extracted data from the selected studies. The following information was collected:

- **Study characteristics:** Author, year of publication, country, and journal.
- **Study design:** Clinical trials, preclinical studies, or systematic reviews.
- **Sample size and patient characteristics:** Age, gender, and cancer stage.
- **Immunotherapy approach:** Type of intervention (immune checkpoint inhibitors, monoclonal antibodies, or adoptive cell therapies).
- **Clinical outcomes:** Overall survival, progression-free survival, and treatment response.

Any discrepancies between the two reviewers were resolved by consultation with a third reviewer.

The data were synthesized using a narrative approach, identifying key trends, therapeutic strategies, and clinical outcomes associated with immunotherapy in OSCC.

5. Risk of Bias Assessment

The quality of the included studies was assessed using standardized tools:

- The Cochrane Risk of Bias Tool was applied to randomized controlled trials (RCTs), evaluating factors such as random sequence generation, allocation concealment, blinding, and incomplete outcome data.
- The Newcastle-Ottawa Scale (NOS) was used for observational studies, assessing selection, comparability, and outcome parameters.

Studies deemed to have a high risk of bias were excluded from the final synthesis to maintain the validity and reliability of the review.

6. Ethical Considerations

Since this research was a systematic review of existing literature, no ethical approval or informed consent was required. However, all included studies adhered to ethical standards outlined by the Declaration of Helsinki or equivalent ethical guidelines. Proper attribution and citation of all original sources were ensured throughout the review process.

Immune Profiling of Oral Cancer

Oral squamous cell carcinoma (OSCC) is a major subtype of head and neck cancer with significant morbidity and mortality rates worldwide. The immune system plays a critical role in determining tumor progression and patient outcomes. Immune profiling of OSCC provides valuable insights into the interaction between immune cells and tumor cells within the tumor microenvironment (TME), shedding light on potential biomarkers, therapeutic targets, and prognostic indicators.

1. Cross Talk Between Immune System and Tumor Cells Within the TME

The TME is a dynamic ecosystem composed of tumor cells, immune cells, stromal cells, and extracellular matrix components. The interplay between immune cells and tumor cells is a decisive factor in OSCC progression. In a healthy immune response, cytotoxic T cells, natural killer (NK) cells, and dendritic cells recognize and eliminate malignant cells. However, OSCC cells develop mechanisms to evade immune surveillance by exploiting immunosuppressive pathways.

Key immune evasion strategies in OSCC include:

- **Immune Checkpoint Expression:** Tumor cells overexpress immune checkpoint molecules such as PD-L1 (programmed death-ligand 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), leading to T-cell exhaustion and immune escape.
- **Recruitment of Immunosuppressive Cells:** OSCC tumors attract immunosuppressive cells, including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), which inhibit cytotoxic T cell activity and promote immune evasion.
- **Tumor-Associated Macrophages (TAMs):** TAMs with an M2 phenotype exert pro-tumoral effects by secreting immunosuppressive cytokines, fostering angiogenesis, and promoting metastasis.

These immunosuppressive mechanisms create a TME that facilitates tumor growth, immune resistance, and poor clinical outcomes.

2. Inflammatory Biomarkers in OSCC

Inflammatory biomarkers play a crucial role in modulating the immune response in OSCC and have been associated with disease progression and prognosis. The key inflammatory biomarkers in OSCC include:

- **Interleukin-6 (IL-6):** IL-6 promotes OSCC proliferation and survival by activating the STAT3 signaling pathway, which induces resistance to apoptosis and enhances tumor invasiveness. Elevated IL-6 levels are linked to poor prognosis.
- **Tumor Necrosis Factor-Alpha (TNF-α):** TNF-α contributes to chronic inflammation in the TME, facilitating tumor growth, angiogenesis, and metastasis.
- **Interleukin-10 (IL-10):** IL-10 is an anti-inflammatory cytokine that suppresses T cell-mediated responses, enabling immune escape and promoting tumor progression.
- **C-Reactive Protein (CRP):** Elevated CRP levels indicate systemic inflammation and are associated with poor survival outcomes in OSCC patients.
- **Neutrophil-to-Lymphocyte Ratio (NLR):** A high NLR is linked to an unfavorable prognosis, as it reflects systemic inflammation and reduced immune surveillance capacity.

These inflammatory markers serve as potential diagnostic and prognostic biomarkers, aiding in risk stratification and treatment planning.

3. Immune Gene Expression Profiling

Gene expression profiling offers insights into the molecular mechanisms underlying immune escape and response in OSCC. Immune-related gene signatures can predict patient outcomes and identify therapeutic targets.

- **PD-L1 and CTLA-4 Overexpression:** OSCC tumors with high PD-L1 and CTLA-4 expression exhibit increased immune evasion capabilities, making these molecules prime candidates for immune checkpoint blockade therapies.
- **FOXP3 (Forkhead Box P3):** FOXP3 is a Treg marker associated with immune suppression. Its overexpression correlates with poor prognosis due to Treg-mediated immune evasion.
- **CD163 (M2 Macrophage Marker):** The expression of CD163, indicative of M2-polarized TAMs, is associated with an immunosuppressive TME and reduced survival.
- **CXCL9 (C-X-C Motif Chemokine Ligand 9):** CXCL9 promotes T cell recruitment and is linked to a favorable prognosis. High CXCL9 expression reflects a more active immune response against OSCC tumors.

Immune gene expression profiling not only offers potential prognostic markers but also guides the selection of immunotherapy targets.

4. Methods Adopted in Immune Profiling

Immune profiling in OSCC employs a variety of techniques to characterize the immune landscape and identify potential therapeutic targets. The most common methods include:

- **Flow Cytometry:** This technique allows for the quantification and characterization of immune cell populations in tumor tissues, providing detailed insights into T cell, NK cell, and myeloid cell subsets.
- **Immunohistochemistry (IHC):** IHC is widely used to detect immune checkpoint proteins (e.g., PD-L1, CTLA-4) and other immune markers in tissue samples, enabling the visualization of immune infiltration patterns.

- **RNA Sequencing (RNA-seq):** Transcriptomic profiling through RNA-seq provides comprehensive data on the expression of immune-related genes, aiding in the identification of immune signatures and therapeutic targets.

- **Multiplex Cytokine Assays:** These assays measure multiple inflammatory mediators simultaneously, offering a detailed inflammatory profile of the TME.

Each of these methods plays a vital role in capturing the complexity of the immune landscape in OSCC, enabling both research and clinical applications.

5. Clinical Use of Immune Profiles in OSCC

The clinical relevance of immune profiling in OSCC lies in its potential to guide personalized therapy and predict treatment responses.

- **Predicting Immunotherapy Response:** Patients with high PD-L1 expression show better responses to PD-1/PD-L1 inhibitors, highlighting the importance of immune profiling in treatment selection.

- **Combination Therapies:** For patients with immunosuppressive TMEs (e.g., enriched with Tregs and M2 macrophages), combination therapies targeting multiple immune pathways (e.g., PD-1/CTLA-4 inhibitors with cytokine modulators) are being explored.

- **Prognostic Biomarkers:** Tumor-infiltrating lymphocytes (TILs) serve as prognostic markers. Higher TIL density is associated with improved survival, while reduced TILs correlate with poor outcomes.

- **Stratifying Patients for Personalized Treatment:** Immune profiling enables patient stratification based on immune signatures, allowing clinicians to design personalized therapeutic regimens that maximize treatment efficacy.

Immunoediting in Oral Cancer

1. Mechanism of Cancer Immunoediting

Cancer immunoediting is a dynamic and complex process that shapes the interaction between the immune system and tumor cells. It consists of three distinct phases: elimination, equilibrium, and escape. These phases collectively influence tumor progression and immune evasion.

- **Elimination Phase:** In the initial phase, the immune system identifies and eradicates emerging tumor cells. Both innate and adaptive immune responses collaborate to eliminate malignant cells. Natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) play critical roles in recognizing and destroying tumor cells through cytotoxic activity and the release of pro-inflammatory cytokines, such as interferon-gamma (IFN-γ). The IFN-γ signaling pathway enhances antigen presentation, promotes apoptosis, and activates immune effector cells, contributing to effective tumor clearance. However, during this phase, some tumor cells may acquire genetic or epigenetic changes that enhance their survival and resistance to immune attack.

- **Equilibrium Phase:** In cases where the immune system cannot completely eliminate all tumor cells, the process enters the equilibrium phase. Here, the immune system continues to exert selective pressure on tumor cells, suppressing their proliferation but failing to eradicate them entirely. This phase can persist for months or even years, during which tumor cells develop adaptive mutations that confer resistance to immune-mediated destruction. The tumor cells that survive this phase may possess reduced immunogenicity or upregulate immune checkpoint molecules, aiding their evasion from immune surveillance.

- **Escape Phase:** Over time, tumor cells that withstand immune pressure undergo further genetic and epigenetic alterations, enabling them to bypass immune recognition and destruction. This phase is characterized by immune suppression and uncontrolled tumor proliferation. Tumor cells in the escape phase often express immune checkpoint molecules, such as programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which inhibit T cell activation and promote immune evasion. Additionally, immunosuppressive cells, including tumor-associated macrophages (TAMs) and regulatory T cells (Tregs), contribute to an immunosuppressive tumor microenvironment (TME), further weakening anti-tumor immunity.

2. Implications of Cancer Immunoediting in Oral Squamous Cell Carcinoma (OSCC) Immunotherapy

Understanding the mechanisms of immunoediting in oral squamous cell carcinoma (OSCC) is essential for developing effective immunotherapeutic strategies. OSCC tumors in the escape phase often exhibit immune evasion characteristics, such as the upregulation of immune checkpoint molecules and recruitment of immunosuppressive cells, which hinder immune-mediated tumor clearance. This has direct implications for current and emerging immunotherapies.

- **Immune Checkpoint Inhibitors (ICIs):** One of the key therapeutic approaches in OSCC involves immune checkpoint blockade. Tumors in the escape phase frequently overexpress PD-L1 and CTLA-4, which suppress T cell activity. ICIs, such as pembrolizumab and nivolumab, target these checkpoint molecules, thereby restoring T cell function and enhancing anti-tumor immunity. Clinical trials have demonstrated the efficacy of ICIs in a subset of OSCC patients, particularly those with PD-L1-positive tumors. However, a significant proportion of patients show limited or no response to ICIs, highlighting the need for predictive biomarkers and combination strategies to enhance therapeutic outcomes.

- **Targeting Tumor-Associated Macrophages (TAMs) and Regulatory T Cells (Tregs):** TAMs and Tregs contribute to immune suppression in the OSCC tumor microenvironment. TAMs promote tumor growth, angiogenesis, and immune evasion by secreting immunosuppressive cytokines, such as IL-10 and TGF-β, while Tregs inhibit effector T cell activity. Therefore, strategies aimed at depleting or reprogramming TAMs and inhibiting Tregs are being explored to enhance immunotherapy efficacy. Agents that block CCL2/CCR2 signaling or promote TAM polarization toward an M1-like phenotype are under investigation. Similarly, Treg-depleting antibodies and FOXP3-targeted therapies are being evaluated for their potential to boost anti-tumor immunity in OSCC.

- **Cancer Vaccines:** Cancer vaccines targeting OSCC-specific antigens represent a promising avenue for generating durable anti-tumor immune responses. Vaccines designed against HPV oncoproteins (e.g., E6 and E7) and mutated tumor-associated proteins are being investigated in clinical trials. By priming the immune system to recognize and attack OSCC cells, these vaccines aim to enhance immunotherapy effectiveness and prevent disease recurrence.

- **Adoptive T Cell Therapy:** Chimeric antigen receptor (CAR)-T cell therapy is emerging as a potential strategy to overcome immune escape mechanisms in OSCC. CAR-T cells are genetically engineered to recognize tumor-specific antigens, enabling them to directly target and eliminate tumor cells. In OSCC, CAR-T cells directed against antigens such as EGFR and MUC1 have shown promise in preclinical studies. However, challenges such as off-target effects, T cell exhaustion, and immunosuppressive TME must be addressed to improve the efficacy and safety of CAR-T cell therapy.

3. Future Directions and Challenges

The complexity of immunoediting in OSCC necessitates a multifaceted approach to immunotherapy. Several key areas require further research:

- **Biomarker Discovery:** Identifying predictive biomarkers for ICI response is critical to stratify patients and optimize treatment efficacy.

- **Combination Therapies:** Combining ICIs with adoptive cell therapies, cancer vaccines, or TME-modulating agents may improve therapeutic outcomes in OSCC patients, particularly those with advanced or recurrent disease.

- **Resistance Mechanisms:** Investigating the molecular and cellular mechanisms underlying immune resistance will aid in the development of next-generation immunotherapies.

- **Personalized Immunotherapy:** Precision medicine approaches, including tumor-specific neoantigen targeting and patient-tailored immunotherapies, hold promise for enhancing treatment responses in OSCC.

Immunotherapy in Oral Cancer: Current Advancements and Future Perspectives

Oral cancer, predominantly represented by oral squamous cell carcinoma (OSCC), remains a major global health burden with high morbidity and mortality rates. Despite advancements in surgery, radiation, and chemotherapy, the prognosis for advanced and recurrent OSCC remains poor. Immunotherapy has emerged as a promising therapeutic modality by harnessing the body's immune system to target and eliminate cancer cells. This review explores the latest advancements in immunotherapy for oral cancer, including immune checkpoint inhibitors (ICIs), targeted monoclonal antibodies, cancer stem cell therapies, cancer vaccines, and emerging combination strategies.

1. Immune Checkpoint Inhibitors (ICIs) in OSCC

ICIs represent a revolutionary approach in the treatment of OSCC by reversing immune suppression and restoring anti-tumor immunity. The programmed death-1 (PD-1) receptor and its ligand, PD-L1, play a key role in immune evasion by OSCC cells. By blocking these interactions, ICIs restore T cell activity, enabling the immune system to effectively target and destroy tumor cells.

- **PD-1 Inhibitors:** Drugs such as pembrolizumab and nivolumab block PD-1 interactions with PD-L1-expressing tumor cells, thereby enhancing T cell responses. Clinical trials have demonstrated improved overall survival (OS) and progression-free survival (PFS) in patients with recurrent or metastatic OSCC receiving these ICIs.

- **Challenges and Biomarkers:** Despite the clinical efficacy of ICIs, only a subset of patients responds favorably. Therefore, predictive biomarkers such as PD-L1 expression levels and tumor mutational burden (TMB) are being explored to identify patients most likely to benefit from ICIs.

2. Targeted Monoclonal Antibodies

Monoclonal antibodies (mAbs) targeting oncogenic pathways involved in OSCC pathogenesis provide an additional therapeutic strategy. These agents are designed to block specific molecular pathways responsible for tumor growth and immune evasion.

- **EGFR-Targeted Therapy:** Cetuximab, an anti-EGFR monoclonal antibody, is approved for OSCC treatment in combination with chemotherapy or radiation therapy. EGFR overexpression is common in OSCC and contributes to tumor proliferation, making it a valuable therapeutic target.

- **VEGF-Targeted Therapy:** Bevacizumab, an anti-VEGF monoclonal antibody, inhibits angiogenesis by blocking VEGF signaling, thereby reducing blood supply to the tumor and enhancing response to treatment.

- **Combination Strategies:** Integrating ICIs with monoclonal antibodies is being investigated as a synergistic approach to enhance anti-tumor immunity and overcome resistance mechanisms.

3. Oral Cancer Stem Cells and Immune Evasion

Cancer stem cells (CSCs) in OSCC play a crucial role in tumor initiation, recurrence, and immune evasion. CSCs exhibit several immune escape mechanisms:

- **PD-L1 Overexpression:** CSCs display high PD-L1 levels, suppressing T cell activation and enabling immune evasion.

- **Cytokine Secretion:** Immunosuppressive cytokines such as **TGF-β** and **IL-10**, secreted by CSCs, further inhibit T cell responses, promoting immune tolerance.

- **CSC-Targeted Immunotherapy:** Novel strategies aim to eradicate CSCs using CSC-specific **CAR-T cells** and differentiation-inducing agents. CAR-T cells engineered to target **EGFR** and **CD44** on CSCs have shown promising preclinical efficacy.

4. Cancer Vaccines in OSCC

Therapeutic cancer vaccines are being developed to stimulate tumor-specific immune responses, offering a potential long-term immunotherapy strategy.

- **Peptide-Based Vaccines:** These vaccines target tumor-associated antigens such as HPV oncoproteins and MAGE-A3. HPV-related OSCC cases, in particular, show potential for vaccine-based immunotherapy.

- **Dendritic Cell (DC) Vaccines:** DC-based vaccines aim to enhance antigen presentation and activate cytotoxic T cells against OSCC cells. Although still in early phases of clinical development, these vaccines hold potential for inducing long-term anti-tumor immunity.

5. Emerging Therapies and Combination Strategies

Adoptive T cell therapy, particularly tumor-infiltrating lymphocyte (TIL) therapy and CAR-T cell therapy, is gaining attention in OSCC immunotherapy.

- **CAR-T Cell Therapy:** CAR-T cells engineered to target OSCC-specific antigens, including EGFR and CD44, have demonstrated encouraging preclinical results.

- **Combination Approaches:** The integration of ICIs with monoclonal antibodies, cancer vaccines, and immunomodulatory agents is being investigated to enhance treatment efficacy. These combination strategies aim to address immune resistance mechanisms and improve patient outcomes.

6. Challenges and Future Directions

Despite the advancements in OSCC immunotherapy, several challenges remain:

- **Patient Selection:** Only a fraction of OSCC patients respond to ICIs, highlighting the need for biomarker-driven patient selection strategies.

- **Immune-Related Toxicities:** ICIs and CAR-T therapies are associated with immune-related adverse events (irAEs), requiring careful management.

- **Resistance Mechanisms:** Tumor heterogeneity and immune escape mechanisms limit the long-term effectiveness of immunotherapy.

- **Future Research:** Future efforts should focus on:

a. Identifying novel immune targets and biomarkers.
b. Improving combination therapy regimens.
c. Personalizing immunotherapy approaches for better clinical outcomes.

Conclusion

Immunotherapy has emerged as a transformative approach in the management of oral squamous cell carcinoma (OSCC), offering new hope for patients with advanced or treatment-resistant disease. Immune checkpoint inhibitors (ICIs), such as pembrolizumab and nivolumab, have demonstrated significant clinical efficacy, although variable response rates and resistance mechanisms remain challenges. The identification of predictive biomarkers, including PD-L1 expression and tumor mutational burden, is essential to refining patient selection and optimizing therapeutic outcomes. Furthermore, innovative immunotherapeutic strategies, including cancer vaccines, monoclonal antibodies, and adoptive cell therapies, continue to evolve, expanding the range of treatment options.

Despite the progress, widespread clinical application of immunotherapy for OSCC is hindered by tumor immune evasion, resistance to ICIs, and immune-related adverse events. Combination strategies that integrate ICIs with chemotherapy, radiation, or targeted agents are being actively explored to enhance treatment efficacy and overcome resistance. Personalized immunotherapy approaches, driven by comprehensive immune profiling and precision medicine, hold the potential to significantly improve patient outcomes.

Future research should prioritize refining combination regimens, identifying novel immunotherapeutic targets, and elucidating the complex interactions within the tumor microenvironment. Advancements in next-generation CAR-T cells, tumor-infiltrating lymphocyte therapy, and neoantigen-based vaccines are promising avenues that could further revolutionize OSCC treatment. As our understanding of tumor immunology continues to expand, ongoing translational research and clinical trials will be vital in harnessing the full potential of immunotherapy, ultimately improving survival and quality of life for patients with OSCC.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin,2020:70(4):313–336.
2. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Krummel MF. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med,2018:24(5):541–550. https://doi.org/10.1038/s41591-018-0014-x
3. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers,2021:7(1):1-21. https://doi.org/10.1038/s41572-021-00258-3
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin,2020:70(4):313–336. https://doi.org/10.3322/caac.21660
5. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol,2002:20(1):825–860. https://doi.org/10.1146/annurev.immunol.20.100301.064020
6. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, *et al*. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med,2016:375(19):1856-1867. https://doi.org/10.1056/NEJMoa1602252

7. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Krummel MF. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med,2018:24(5):541–550. https://doi.org/10.1038/s41591-018-0014-x
8. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, *et al*. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic head and neck squamous cell carcinoma: A phase 1b study. Lancet Oncol,2016:17(7):956-965.
9. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, *et al*. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet,2019:394(10212):1915-1928. https://doi.org/10.1016/S0140-6736(19)32591-7
10. Hanna GJ, Woo SB, Li Y, Bar-Ad V, Hadlock T, Tishler RB, Haddad RI. The role of immunotherapy in head and neck squamous cell carcinoma: A review. JAMA Otolaryngol Head Neck Surg,2020:146(11):775-783. https://doi.org/10.1001/jamaoto.2020.1691
11. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, *et al*. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med,2008:357(17):1695–1704.
12. Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, *et al*. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight,2020:1(17):e89829. https://doi.org/10.1172/jci.insight.89829
13. Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Depil S, Meylan E. Cold tumors: A therapeutic challenge for immunotherapy. Front Immunol,2019:10:168. https://doi.org/10.3389/fimmu.2019.00168
14. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med,2018:378(2):158-168. https://doi.org/10.1056/NEJMra1703481
15. Cohen EE, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, *et al*. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet,2019:393(10167):156-167. https://doi.org/10.1016/S0140-6736(18)31999-8
16. Hanna GJ, Woo SB, Li Y, Bar-Ad V, Hadlock T, Tishler RB, Haddad RI. The role of immunotherapy in head and neck squamous cell carcinoma: A review. JAMA Otolaryngol Head Neck Surg,2020:146(11):775-783. https://doi.org/10.1001/jamaoto.2020.1691
17. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med,2018:378(2):158-168. https://doi.org/10.1056/NEJMra1703481
18. Hanna GJ, Woo SB, Li Y, Bar-Ad V, Hadlock T, Tishler RB, Haddad RI. The role of immunotherapy in head and neck squamous cell carcinoma: A review. JAMA Otolaryngol Head Neck Surg,2020:146(11):775-783. https://doi.org/10.1001/jamaoto.2020.1691
19. Page MJ, McKenzie JE, Bossuyt PM, *et al*. PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ,2021:372:n160.
20. Moher D, Liberati A, Tetzlaff J, *et al*. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med,2009:6(7):e1000097.
21. Liberati A, Altman DG, Tetzlaff J, *et al*. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med,2009:6(7):e1000100.
22. Higgins JPT, Altman DG, Gøtzsche PC, *et al*. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ,2011:343:d5928.
23. Higgins JPT, Thomas J, Chandler J, *et al*. Cochrane handbook for systematic reviews of interventions. Wiley-Blackwell, 2019.
24. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA,2013:310(20):2191–2194.
25. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Krummel MF. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med,2018:24(5):541–550. https://doi.org/10.1038/s41591-018-0014-x
26. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, *et al*. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med,2016:375(19):1856-1867. https://doi.org/10.1056/NEJMoa1602252
27. Kumar AT, Knops A, Swendseid B, *et al*. The role of tumor-associated macrophages in oral squamous cell carcinoma and insights into therapeutic implications. Front Oncol,2020:10:620.
28. Yang X, Wang F, Wang Z, *et al*. IL-6 promotes oral squamous cell carcinoma progression via JAK2/STAT3 signaling pathway activation. Cancer Cell Int,2019:19(1):263.
29. Chen YP, Wang YQ, Lv JW, *et al*. Identification and validation of novel immune-related gene signatures for predicting prognosis in oral squamous cell carcinoma. Front Oncol,2020:10:561.
30. Fang J, Li X, Ma D, *et al*. Inflammatory markers and risk of oral squamous cell carcinoma recurrence and survival: A systematic review and meta-analysis. Clin Transl Oncol,2021:23(3):529-538.
31. Shen Z, Guo Y, Zhang Q, *et al*. Immune-related gene signatures associated with prognosis and tumor microenvironment in oral squamous cell carcinoma. Cancer Immunol Immunother,2021:70(5):1207-1221.
32. Outh-Gauer S, Altchek A, Dumenil C, de Marassé C, Cosmidis A, Bertolus C, Bakhos D. Immune biomarkers and immunotherapy in head and neck squamous cell carcinoma: A review. Oral Oncol,2021:115:105191.
33. Galon J, Bruni D, Angell HK, *et al*. The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic insights. Immunity,2020:52(3):432-450.
34. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, *et al*. The immune landscape of cancer. Immunity,2018:48(4):812-830.e14.

35. Schoenfeld JD, Hanna GJ. Immunotherapy for head and neck squamous cell carcinoma. Hematol Oncol Clin North Am,2018:33(2):301-321.
36. Balermpas P, Rodel F, Weiss C, *et al*. Tumor-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer,2017:117(2):183-190.
37. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol,2002:20(1):825–860. https://doi.org/10.1146/annurev.immunol.20.100301.064020
38. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science,2011:331(6024):1565-1570.
39. Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res,2015:21(4):687-692.
40. Ferris RL, Blumenschein G, Fayette J, *et al*. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med,2016:375(19):1856-1867.
41. Hanna GJ, Schoenfeld JD. Immune checkpoint inhibitors in head and neck cancers: From research to practice. Clin Cancer Res,2020:26(3):611-617.
42. Kumar AT, Knops A, Swendseid B, *et al*. The role of tumor-associated macrophages in oral squamous cell carcinoma and insights into therapeutic implications. Front Oncol,2020:10:620.
43. Galon J, Bruni D, Angell HK, *et al*. The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic insights. Immunity,2020:52(3):432-450.
44. Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, *et al*. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight,2020:1(17):e89829. https://doi.org/10.1172/jci.insight.89829
45. Bonaventura P, Shekarian T, Alcazer V, *et al*. Cold tumors: A therapeutic challenge for immunotherapy. Front Immunol,2019:10:168.
46. Ferris RL, Blumenschein G, Fayette J, *et al*. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med,2016:375(19):1856-1867.
47. Burtness B, Harrington KJ, Greil R, *et al*. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-048): A randomized, open-label, phase 3 study. Lancet,2019:394(10212):1915-1928.
48. Cohen EE, Bell RB, Bifulco CB, *et al*. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck. J Immunother Cancer,2019:7(1):184.
49. Hanna GJ, Schoenfeld JD. Immune checkpoint inhibitors in head and neck cancers: From research to practice. Clin Cancer Res,2020:26(3):611-617.
50. Ono T, Kurita H, Kitajima H, *et al*. CD44 variant 3+ cancer stem cells drive tumor immune escape in oral squamous cell carcinoma. Cancer Sci,2020:111(8):2813-2823.
51. Massarelli E, William W, Johnson F, *et al*. Combining immune checkpoint blockade and tumor-specific vaccine for immunotherapy of head and neck squamous cell carcinoma. J Immunother Cancer,2019:7(1):281.
52. Wang X, Li S, Liu X, *et al*. Dendritic cell vaccines for cancer immunotherapy: The role in head and neck squamous cell carcinoma. Front Oncol,2021:11:706972.
53. Bonaventura P, Shekarian T, Alcazer V, *et al*. Cold tumors: A therapeutic challenge for immunotherapy. Front Immunol,2019:10:168.
54. Schoenfeld JD, Hanna GJ. Immunotherapy for head and neck squamous cell carcinoma. Hematol Oncol Clin North Am,2018:33(2):301–321.